Fixed drug eruptions with diverse cutaneous manifestations: Tracing the offending drug was difficult task

Authors

  • Khalifa E Sharquie Department of Dermatology, College of Medicine, University of Baghdad, Center of Dermatology, Medical City Teaching Hospital, Baghdad, Iraq
  • Mazin Hamid Ayyash Department of Dermatology, College of Medicine, Tikrit University, Salahaddin, Iraq
  • Inas K. Sharquie Department of Microbiology & Immunology, College of Medicine, University of Baghdad, Baghdad, Iraq
  • Thamir A Kubaisi Department of Dermatology, College of Medicine, University of Anbar; Ramadi, Anbar, Iraq

Keywords:

Fixed drug eruptions, Red bullous rash, Dusky red patches, Dermal pigmentation

Abstract

Objective Fixed drug eruption is a common dermatological skin problem with acute and chronic consequences and with different clinical manifestations. The offending drugs are numerous but it is often difficult to specify them in many cases. The purpose of the study is to collect a large series of patients to clarify the difference between new and old clinical manifestations and to pinpoint the offending drugs.   Methods This is a case series descriptive study where all patients with certain diagnoses of fixed drug eruption that were seen during the period from January 2014 to June 2023 were collected and analyzed regarding the demographic and clinical features. In addition, a full clinical examination was carried out including the acute, recurrent and chronic sequelae. The tracing for the insulting drugs was tried in the new and old cases.   Results The analysis of 68 cases revealed that their ages ranged from 10-55 years, with males to female’s ratio of 2:1. The disease was acute in (88.2%) patients, and characterized by dusky red patches, or bright red. Also, some lesions were dusky red bullous. Frequently associated with itching and burning. The chronic cases showed well circumscribed patches and macules with deep dermal melanosis. The common sites of lesions were penile in 33.82%, trunk in 17.64%, lips in 14.7%, hands in 11.76%, face in 7.35% of cases. The offending drugs were only detected in 5 (7.35%) participants.   Conclusion Fixed drug eruption is a common cutaneous medical problem with diverse clinical manifestations and on healing, leaves permanent or long-lasting dermal pigmentation. Tracing for the offending drug is very difficult.  

References

Baird BJ, De Villez RL. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol. 1988;27(3):170-4.

Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol. 1998;37(11):833-8.

Flowers H, Brodell R, Brents M, Wyatt JP. Fixed drug eruptions: presentation, diagnosis, and management. South Med J. 2014; 107(11):724-7.

Lisi P, Stingeni L. Fixed drug eruption: bullous form. Clin Dermatol. 1993;11(4):461-6.

Zaouak A, Ben Salem F, Ben Jannet S, Hammami H, Fenniche S. Bullous fixed drug eruption: A potential diagnostic pitfall: a study of 18 cases. Therapie. 2019;74(5):527-30.

Ben Fadhel N, Chaabane A, Ammar H, Ben Romdhane H, Soua Y, Chadli Z, et al. Clinical features, culprit drugs, and allergology workup in 41 cases of fixed drug eruption. Contact Dermatitis. 2019; 81(5):336-40.

atoulis AC, Bozi E, Kanelleas A, Makris M, Alevizou A, Panagiotides I, et al. Psoriasiform fixed drug eruption caused by nimesulide. Clin Exp Dermatol. 2009; 34(7):e360-e361.

Raizada A, Panda M, Dixit N, Lachure A. Psoriasiform fixed-drug eruption to ibuprofen: A rare variant of fixed-drug eruption in a child. Indian J Paediatr Dermatol. 2021;22(1):96-8.

Senturk N, Yanik F, Yildiz L, Aydin F, Canturk T, Turanli AY. Topotecan‐induced cellulitis‐like fixed drug eruption. J Eur Acad Dermatol Venereol. 2002;16(4):414-6.

Singhal RR, Sheth NK, Nair PA. Non-pigmented fixed drug eruption caused by ibuprofen. Indian Dermatol Online J. 2019;10(3):341.

Das A, Sancheti K, Podder I, Das NK. Azithromycin induced bullous fixed drug eruption. Indian J Pharmacol. 2016;48(1):83-5.

Kanwar A, Bharija S, Belhaj M. Fixed drug eruptions in children: a series of 23 cases with provocative tests. Dermatology. 1986;172(6):315-8.

Bhargava N, Singh C. Fixed eruption due to two unrelated drugs: Oxyphenbutazone and tetracycline. Int J Dermatol. 1981; 20(6):435.

JM K. Fixed food eruption. J Am Acad Dermatol. 1996;35:638-9.

Kubota Y. A case of fixed eruption due to tonic water. Arerugi. 2003;52(4):447-9.

Volz T, Berner D, Weigert C, Röcken M, Biedermann T. Fixed food eruption caused by asparagus. J Allergy Clin Immunol. 2005;116(6):1390-2.

Boyle J, Moul B. Fixed drug eruption masquerading as herpes simplex labialis. Br Med J. 1984;289(6448):802.

Vissing MB, Bhasin A, Sluzevich J. The role and histopathology of oral drug challenge in the evaluation of fixed drug eruptions. J Cutan Immunol Allergy. 2021;4(5):120-2.

Tsuruta D, Sowa J, Kobayashi H, Ishii M. Fixed food eruption caused by lactose identified after oral administration of four unrelated drugs. J Am Acad Dermatol. 2005;52(2):370-1.

Mizukawa Y, Yamazaki Y, Shiohara T. In vivo dynamics of intraepidermal CD8+ T cells and CD4+ T cells during the evolution of fixed drug eruption. Br J Dermatol. 2008;158(6):1230-8.

Shiohara T. Fixed drug eruption: pathogenesis and diagnostic tests. Curr Opin Allergy Clin Immunol. 2009;9(4):316-21.

Criado PR. Adverse drug reactions. Dermatology in Public Health Environments: A Comprehensive Textbook: Springer 2023:749-806.

Mizukawa Y, Yamazaki Y, Teraki Y, Hayakawa J, Hayakawa K, Nuriya H. Direct evidence for interferon-γ production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002;161(4):1337-47.

Teraki Y, Shiohara T. IFN-γ–producing effector CD8+ T cells and IL-10–producing regulatory CD4+ T cells in fixed drug eruption. J Allergy Clin Immunol. 2003;112(3):609-15.

Anderson HJ, Lee JB. A review of fixed drug eruption with a special focus on generalized bullous fixed drug eruption. Medicina. 2021;57(9):925.

Lellig E, Mouton-Faivre C, Abs D, Bursztejn AC. Fixed drug eruption after Pfizer-BioNTech COVID-19 vaccine: A case report. J Allergy Clin Immunol Pract. 2022;10(7):1922-3.

Heng YK, Yew YW, Lim DS, Lim YL. An update of fixed drug eruptions in S ingapore. J Eur Acad Dermatol Venereol. 2015;29(8):1539-44.

Al-Sudany, Nameer & Saeed, Mohammad & Al Chalabi, Qasim. Common clinical patterns of fixed drug eruptions among Iraqi patients. A multicenter study. Azerbaijan Med Assoc J. 2022;62:4747-56.

Lim WS, Kim DH, Jin SY, Choi YS, Lee SH, Huh HJ, et al. A case of fixed drug eruption due to doxycycline and erythromycin present in food. Allergy Asthma Immunol Res. 2013;5(5):337-9.

Pai VV, Kikkeri NN, Athanikar S B, Shukla P, Bhandari P, Rai V. Retrospective analysis of fixed drug eruptions among patients attending a tertiary care center in Southern India. Indian J Dermatol Venereol Leprol. 2014;80:194.

Brahimi N, Routier E, Raison-Peyron N, Tronquoy AF, Pouget-Jasson C, Amarger S, et al. A three-year-analysis of fixed drug eruptions in hospital settings in France. Eur J Dermatol. 2010;20(4):461-4.

Özkaya E. Oral mucosal fixed drug eruption: characteristics and differential diagnosis. J Am Acad Dermatol. 2013;69(2):e51-e58.

Agarwal A, Das A, Panda M, Kumar P. Uncommon variants of fixed drug eruption. Indian J Dermatol Venereol Leprol. 2023;89(3):475-81.

Downloads

Published

2024-07-02

How to Cite

1.
Sharquie K, Ayyash MH, Sharquie IK, Kubaisi TA. Fixed drug eruptions with diverse cutaneous manifestations: Tracing the offending drug was difficult task . J Pak Assoc Dermatol [Internet]. 2024Jul.2 [cited 2024Oct.5];34(3):649-56. Available from: https://jpad.com.pk/index.php/jpad/article/view/2630

Issue

Vol. 34 No. 3 (2024): July-September

Section

Original Articles

Most read articles by the same author(s)